Incannex Healthcare earns R&D award for OSA

Incannex Healthcare Inc. reported that on January 15, 2026 it won a Research and Development Award for its obstructive sleep apnea program in the 2025 Clinical Trials Arena Excellence Awards.

Accepted by SEC EDGAR 01/15/2026 - 07:30 AM EST

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Incannex Healthcare Inc. reported that on January 15, 2026 it won a Research and Development Award for its obstructive sleep apnea program in the 2025 Clinical Trials Arena Excellence Awards. This recognition highlights the company’s work in developing treatments for obstructive sleep apnea.

The company also noted that additional details about the award and the program are provided in a press release, which is included as Exhibit 99.1 to this report and incorporated by reference.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Incannex Healthcare Inc. (IXHL) announce in this 8-K filing?

Incannex Healthcare Inc. announced that it won a Research and Development Award for its obstructive sleep apnea program in the 2025 Clinical Trials Arena Excellence Awards.

Which Incannex Healthcare program received the award mentioned for IXHL?

The award relates to Incannex Healthcare’s research and development program focused on obstructive sleep apnea.

When did Incannex Healthcare Inc. (IXHL) receive the R&D award?

Incannex Healthcare Inc. reported that it received the Research and Development Award on January 15, 2026.

What is the name of the award Incannex Healthcare (IXHL) received?

The company received a Research and Development Award in the 2025 Clinical Trials Arena Excellence Awards.

Where can investors find more details on Incannex Healthcare’s award?

More information is provided in a press release attached as Exhibit 99.1, which is incorporated by reference into the report.

Does the 8-K filing for IXHL include financial statements?

No, the 8-K focuses on the Research and Development Award and lists a press release as Exhibit 99.1 without including financial statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 15, 2026

Incannex Healthcare Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-41106

93-2403210

(State or other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

Suite 105, 8 Century Circuit Norwest,

NSW 2153 Australia

Not applicable

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, including Area Code: +61 409 840 786

(Former Name or Former Address, if Changed Since Last Report): Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common Stock, $0.0001 par value per share		IXHL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 15, 2026, Incannex Healthcare Inc. Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards. Further information is included in the press release attached as Exhibit 99.1 hereto, which is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of Incannex Healthcare Inc., dated January 15, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Incannex Healthcare Inc.

Date: January 15, 2026	/s/ Joel Latham
	Name:	Joel Latham
	Title:	Chief Executive Officer and President

Source: View Original Filing on SEC EDGAR